



Provincial Health Services Authority

University of British Columbia
BC Cancer Research Ethics Board

UBC BC Cancer REB

UBC BC Cancer Research Ethics Board

Fairmont Medical Building
750 West Broadway, Suite 1315
Vancouver, B.C. V5Z 1J3
Tel: (604) 877-6284 Fax: (604) 708-2132
Email REB Admin: reb@bccancer.bc.ca
Website: www.bccancer.bc.ca > Research Ethics
RISe: <https://rise.ubc.ca>

UBC BC CANCER RESEARCH ETHICS BOARD MEMBERSHIP LIST

List #82, effective December 12, 2022

UBC BC Cancer Research Ethics Board (REB) institution or organization (IORG) number: IORG0003172
UBC Federal Wide Assurance Number for U.S. government studies: FWA00001149
UBC BC Cancer REB IRB Registration Number: IRB00003797

UBC BC Cancer REB VOTING MEMBER Gender/Canadian Citizenship or Permanent Resident		REB POSITION (Alternate Designation)	HIGHEST DEGREE(S)	PRIMARY SCIENTIFIC or NON SCIENTIFIC SPECIALITY	BC Cancer AFFILIATION	QUOROM DESIGNATION*
1.	Dr. Karen Gelmon Female/Yes	Voting Member Chair	MBBS	Medical Oncology	Yes	S
2.	Dr. Vivien Bramwell Female/Yes	Voting Member Vice-Chair	PhD/MBBS	Medical Oncology	Yes	S
3.	Dr. Holly Longstaff Female/Yes	Voting Member (Alternate for J. Gill)	PhD	Bioethics	No	E, C, N
4.	Ms. Jo-Ann Isaacson Female/Yes	Voting Member	n/a	Community Member	No	C, N
5.	Dr. Doran Ksienski Male/Yes	Voting Member	MD	Medical Oncology	Yes	S
6.	Dr. Heather Sutherland Female/Yes	Voting Member	MD	Medical Oncology/Hematology	Yes	S
7.	Dr. Isabelle Vallieres Female/Yes	Voting Member	MD	Radiation Oncology	Yes	S
8.	Ms. Sylvie Labelle Female/Yes	Voting Member	MSc	Pharmacy	Yes	S
9.	Dr. Alice Hawkins Virani Female/Yes	Voting Member(Alternate for J Gill)	PhD	Bioethics/Human Genetics	No	E, C, S
10.	Dr. Ardis Krueger Female/Yes	Ad Hoc Member	ND	Complementary and Alternative Medicine	No	S, H, C
11.	Dr Aalok Kumar Male/Yes	Voting Member	MD	Medical Oncology	Yes	S

12.	Dr Nina Preto Female/Yes	Voting Member (Alternate for J Gill)	PhD	Bioethics	Yes	E, C, N
13.	Ms Julie Gibson Female/Yes	Voting Member	JD	Law	No	L
14.	Ms Patricia (Pat) Evans Female/Yes	Voting Member (Alternate for J Isaacson)	BA	Community Member	No	C
15.	Ms Elizabeth Kinney Female/Yes	Voting Member (Alternate for J Gibson)	JD	Law	No	L
16.	Dr Anita Ho Female/Yes	Voting Member (Alternate for J Gill)	PhD	Bioethics	No	E
17.	Mr Matthew Voell Male/Yes	Voting Member (Alternate for J Gibson)	JD	Law	No	L
18.	Mr Neil Hain Male/Yes	Voting Member (Alternate for J Gibson)	LLB	Law	No	L
19.	Ms Julia Gill Female/Yes	Voting Member (Alternate for J Gill)	MHSc	Bioethics	No	E
20.	Dr Brandon Bernard Male/Yes	Voting Member	MD/MPH	Medical Oncology	Yes	S
21.	Dr Krista Noonan Female/Yes	Voting Member	MD	Medical Oncology	Yes	S
22.	Dr. Anna Hayden Female/Yes	Voting Member	MD	Hematology	Yes	S
23.	Dr Jane Ingman-Baker Female/Yes	Voting Member (Alternate for J Gibson)	LLB, PhD	Law	No	L
24.	Dr. Hamid Raziee Male/Yes	Voting Member	MD	Radiation Oncology	Yes	S
25.	Ms. Tamsin Tarling Female/Yes	Ad Hoc Member	MSc	Scientific (Biobanking)	Yes	S
26.	Ms. Brittney Schichter Female/Yes	Voting Member (Alternate for J Gill)	JD	Bioethics	No	E
27.	Dr. Matthew Chan Male/Yes	Voting Member	MD	Radiation Oncology	Yes	S
28.	Dr. Nicole Chau Female/Yes	Voting Member	MD	Medical Oncology	Yes	S
29.	Dr. Jack Zheng Male/Yes	Voting Member	MD	Radiation Oncology	Yes	S

*A quorum comprises a minimum of five separate members from groups 1-4 with one from group 2-4 fulfilling group 5 voting in favour.

(1) at least two members with broad expertise in biomedical research; (Scientific): **S**

(2) at least one member knowledgeable in the ethics of scientific research: **E**

(3) at least one member knowledgeable in law relevant to scientific research: **L**

(4) at least one member from the community who has no affiliation with the institution: **C**

(5) at least one member whose specialty is non-scientific (may be one of the members from groups 2-4): **N**

(6) at least one member knowledgeable in therapeutic natural health products (ad hoc for review of therapeutic natural health products) **H**

Changes reflected in this document:

- Added: Dr. Jack Zheng

FOR ALL RESEARCH CONDUCTED UNDER THIS ASSURANCE, THE UBC BC CANCER REB CHAIRPERSON HEREBY ATTESTS THAT, EXCEPT WHERE SPECIFICALLY WAIVED OR ALTERED BY THE REB UNDER 45 CFR 46.116(c), 46.116(d), or 46.117(c), THE REB WILL UPHOLD THE REQUIREMENTS OF 45 CFR 46 FOR WRITTEN INFORMED CONSENT, IN NONEXCULPATORY LANGUAGE UNDERSTANDABLE TO THE SUBJECT (OR THE SUBJECT’S LEGALLY AUTHORIZED REPRESENTATIVE), INCLUDING THE FOLLOWING BASIC ELEMENTS PER 45 CFR 46.116(a/b):

- (1) IDENTIFICATION AS RESEARCH PURPOSES, DURATION, AND PROCEDURES; PROCEDURES WHICH ARE EXPERIMENTAL;
- (2) REASONABLY FORESEEABLE RISKS OR DISCOMFORTS;
- (3) EXPECTED BENEFITS TO THE SUBJECT OR OTHERS;
- (4) ALTERNATIVE PROCEDURES OR TREATMENTS;
- (5) EXTENT OF CONFIDENTIALITY TO BE MAINTAINED;
- (6) WHETHER COMPENSATION OR MEDICAL TREATMENT ARE AVAILABLE IF INJURY OCCURS (IF MORE THAN MINIMAL RISK)
- (7) WHOM TO CONTACT FOR ANSWERS TO QUESTIONS ABOUT THE RESEARCH, SUBJECT’S RIGHTS, AND RESEARCH-RELATED INJURY;
- (8) PARTICIPATION IS VOLUNTARY, REFUSAL TO PARTICIPATE WILL INVOLVE NO PENALTY OR LOSS OF BENEFITS TO WHICH THE SUBJECT IS ENTITLED; SUBJECT MAY DISCONTINUE AT ANY TIME WITHOUT PENALTY OR LOSS OF BENEFITS TO WHICH SUBJECT IS ENTITLED;
- (9) WHEN APPROPRIATE, ADDITIONAL ELEMENTS PER 45 CFR 46.116(b).

AS UBC BC CANCER REB CHAIRPERSON, I HEREBY SO ATTEST:

SIGNATURE:



Dr. K Gelmon

DATE: December 12, 2022
 PHONE: (604) 877-6284
 ADDRESS: 750 West Broadway, Suite 1315
 Vancouver, B.C. V5Z 1J3